Cancer Discovery, 15, 83-104
2024

Chromothripsis-Mediated Small Cell Lung Carcinoma

Natasha Rekhtman, Sam E. Tischfield, Christopher A. Febres-Aldana, Jake June-Koo Lee, Jason C. Chang et al.

<p>Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically associated with tobacco exposure and inactivation of <em>RB1</em> and <em>TP53</em> genes. Here, we performed detailed clinicopathologic, genomic, and transcriptomic profiling of an atypical subset of SCLC that lacked <em>RB1</em> and <em>TP53</em> co-inactivation and arose in never/light smokers. We found that most cases were associated with chromothripsis—massive, localized chromosome shattering—recurrently involving chromosome 11 or 12 and resulting in extrachromosomal amplification of <em>CCND1</em> or co-amplification of <em>CCND2</em>/<em>CDK4</em>/<em>MDM2</em>, respectively. Uniquely, these clinically aggressive tumors exhibited genomic and pathologic links to pulmonary carcinoids, suggesting a previously uncharacterized mode of SCLC pathogenesis via transformation from lower-grade neuroendocrine tumors or their progenitors. Conversely, SCLC in never-smokers harboring inactivated <em>RB1</em> and <em>TP53</em> exhibited hallmarks of adenocarcinoma-to-SCLC derivation, supporting two distinct pathways of plasticity-mediated pathogenesis of SCLC in never-smokers.</p> <p><strong>Significance:</strong> Here, we provide the first detailed description of a unique SCLC subset lacking <em>RB1</em>/<em>TP53</em> alterations and identify extensive chromothripsis and pathogenetic links to pulmonary carcinoids as its hallmark features. This work defines atypical SCLC as a novel entity among lung cancers, highlighting its exceptional histogenesis, clinicopathologic characteristics, and therapeutic vulnerabilities.</p>

Digital object identifier (DOI): 10.1158/2159-8290.cd-24-0286

All Publications